Effects of cilostazol on heart rate and its variability in patients with sick sinus syndrome

Clinical Drug Investigation

Volumn 21, Issue 9, 2001, Pages 605-612

  Tsuji, T ^a   Ueda, H ^a   Nakatsu, T ^b   Murakami, T ^a   Kusachi, S ^b   Tominaga, Y ^b   Yamane, S ^a   Uesugi, T ^a   Komatsubara, I ^a   Iwabu, A ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Yashima General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CILOSTAZOL;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART RATE; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; SICK SINUS SYNDROME;

EID: 0034773909     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121090-00002     Document Type: Article

References (23)

1. The sick sinus syndrome
2. Survival and follow-up after pacemaker implantation: A comparison of patients with sick sinus syndrome, complete heart block, and atrial fibrillation
3. Long-term survival after permanent pacemaker implantation for sick sinus syndrome
4. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography
5. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities
6. Effects of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency
7. LY195115: A potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum
8. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics
9. Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias
10. Heart rate variability
11. Heart rate variability index in congestive heart failure: Relation to clinical variables and prognosis
12. Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure
13. Synthesis of atrial natriuretic polypeptide in human failing hearts. Evidence for altered processing of atrial natriuretic polypeptide precursor and augmented synthesis of beta-human ANP
14. Clinical spectrum of the sick sinus syndrome
15. Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects
16. Novel and ultrasensitive noncompetitive enzyme immunoassay (hetero-two-site complex transfer enzyme immunoassay) for alpha-human atrial natriuretic peptide
17. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man
18. Xamoterol in severe heart failure
19. Effect of oral milrinone on mortality in severe chronic heart failure
20. Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure
21. Heart rate variability as a means of assessing prognosis after acute myocardial infarction. A 3-year follow-up study
22. Heart rate variability in idiopathic dilated cardiomyopathy: Relation to disease severity and prognosis
23. ACC/AHA guidelines for implication of cardiac pacemakers and anti-arrhythmia devices: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation)